

onco
invent



Results of the 2nd Quarter 2020



Jan A. Alfheim
CEO

Agenda

1. Welcome to the 2nd Quarter 2020 presentation
2. Results from the 2nd Quarter
3. Financials
4. Q&A




Results from the 2nd Quarter



Radspherin[®] clinical trials start

- The first patient dosed with Radspherin[®] in a Phase 1 clinical trial targeting colorectal cancer patients suffering from peritoneal carcinomatosis 2. June
- On 11. June Oncoinvent announced that the first patient in the ovarian cancer trial had been treated with Radspherin[®]
- Both trials are ongoing at the Radium Hospital in Oslo
- 5 patients have been enrolled
- Study centers in Leuven, Belgium and Uppsala, Sweden expected to open in Q3



Clinical experience so far

- The Safety Advisory Committee responsible for RAD-18-002 will be meeting to assess the safety of a 1 MBq dose of Radspherin
- Imaging indicates that the administration of Radspherin has been successful and that a relatively even distribution of product has been observed in the peritoneal cavity of patients

Oncoinvent raises 49 MNOK

- In the second quarter Oncoinvent secured financing through a private placement of NOK 40 mill.
- The round was led by Hadean Ventures and existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS participated
- The subsequent repair offering was oversubscribed, securing additional proceeds of NOK 9 mill.
- The financing released an additional NOK 4.6 million of non-dilutive funding from Innovation Norway

New board member elected



Ingrid Teigland Akay is a medical doctor and Managing Partner of Hadean Ventures, a European life science fund manager with offices in Oslo and Stockholm. Ingrid has over a decade's experience working within life science venture capital, supporting companies both in Europe and the US. Prior to establishing Hadean Ventures, Ingrid was working for Inventages, a London-based, global life science VC firm. Before her investment career, Ingrid worked within surgery and internal medicine at hospitals in Norway and the UK. Ingrid holds a medical degree from Medizinische Hochschule Hannover, as well as an MBA in Finance from London Business School.



Financials



Q2-2020 Financial figures

KEY FIGURES AMOUNTS IN NOK	2nd QUARTER		YTD		FULL YEAR
	2020	2019	2020	2019	2019
TOTAL REVENUES AND OTHER INCOME	2 970 666	339 000	3 020 666	1 569 730	11 411 529
Payroll and related expenses	6 254 119	4 127 643	12 818 920	10 696 955	23 883 378
Other operating expenses	9 488 796	5 869 815	15 986 855	12 552 688	26 964 978
TOTAL OPERATING EXPENSES	15 742 914	9 997 458	28 805 775	23 249 643	50 848 356
EBITDA	- 12 772 248	- 9 658 458	- 25 785 109	- 21 679 913	- 39 436 827
Depreciation and amortization	1 360 479	1 088 168	2 498 035	1 088 168	4 434 609
EBIT	- 14 132 727	- 10 746 626	- 28 283 144	- 22 768 081	- 43 871 436
Finance cost and other income	100 902	11 030	43 366	21 626	1 672 053
NET PROFIT(LOSS) FOR THE PERIOD	- 14 031 825	- 10 735 596	- 28 239 778	- 22 789 707	- 42 199 383
Net Proceeds from equity issue	49 524 888	125 000	49 524 888	125 000	125 000
Cash and cash equivalents, end of period	140 978 278	135 080 934	140 978 278	135 080 934	118 337 860
Total number of shares, beginning of period	13 190 411	13 187 181	13 190 411	13 187 181	13 190 411
Total number of shares, end of period	14 306 904	13 190 411	14 306 904	13 190 411	13 190 411



Q & A



onco
invent